A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable or recurrent. 2) Only subjects with positive mesothelin expression (Ventana mesothelin [MSLN]- immunohistochemistry [IHC]; Negative=H-score =< 10) are eligible. 3) Patients must have received and either progressed or been intolerant to at least 1 systemic therapy. 4) Life expectancy of at least 3 months.

You may not be eligible for this study if the following are true:

  • 1) Participation in another clinical study with an investigational product during the last 28 days or 5 half-lives prior to study Day 1, whichever is shorter. 2) Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression. 3) Any major surgery within 4 weeks of study drug administration.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.